Literature DB >> 25129100

Microvascular lesions by estrogen-induced ID3: its implications in cerebral and cardiorenal vascular disease.

Jayanta K Das1, Quentin Felty.   

Abstract

Severe symptoms of cerebral and cardiorenal vascular diseases can be triggered when cerebral, coronary, or glomerular arterioles grow inappropriately as a result of abnormal cell proliferation. The risk factor(s) and molecular mechanisms responsible for microvascular lesion formation are largely unknown. Although controversial, both animal and epidemiological studies have shown that estrogen increases the risk of stroke which may be due to microvascular lesions. Since microvascular diseases are characterized by excessive vessel growth, it is plausible that estrogen-induced neovascularization contributes to the growth of microvascular lesions. We present evidence for how ID3 overexpression in endothelial cells contributes to the development of an estrogen-induced neovascular phenotype with an additional focus on Pyk2 kinase. Our data showed that ID3 overexpression increased neovascularization, cell migration, and spheroid growth of human cerebral microvascular endothelial cells, hCMEC/D3. ID3-overexpressing cells showed significant estrogen-induced G2/M phase transition. Estrogen treatment increased both ID3 phosphorylation; total protein that was inhibited by tamoxifen, and Pyk2-mediated estrogen-induced ID3 mRNA expression. These findings suggest that Pyk2 signals ID3 expression and ID3 is necessary for estrogen-induced neovascularization in hCMEC/D3 cells. A better understanding of how microvascular lesions depend on ID3 may open new avenues for prevention and treatment of neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25129100      PMCID: PMC4320014          DOI: 10.1007/s12031-014-0401-9

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  39 in total

1.  Phosphorylation regulates Id3 function in vascular smooth muscle cells.

Authors:  Scott T Forrest; Angela M Taylor; Ian J Sarembock; Demetra Perlegas; Coleen A McNamara
Journal:  Circ Res       Date:  2004-08-19       Impact factor: 17.367

Review 2.  Spatial and temporal dynamics of the endothelium.

Authors:  W C Aird
Journal:  J Thromb Haemost       Date:  2005-05-09       Impact factor: 5.824

3.  Influence of angiogenesis inhibitors on endothelial cell morphology in vitro.

Authors:  Tina Friis; Alastair B Hansen; Gunnar Houen; Anne-Marie Engel
Journal:  APMIS       Date:  2006-03       Impact factor: 3.205

4.  Estrogen-induced redox sensitive Id3 signaling controls the growth of vascular cells.

Authors:  Quentin Felty; Nicole Porther
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

5.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

Authors:  S D Lee; K R Shroyer; N E Markham; C D Cool; N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

6.  Estradiol increases brain lesions in the cortex and lateral striatum after transient occlusion of the middle cerebral artery in rats: no effect of ischemia on galanin in the stroke area but decreased levels in the hippocampus.

Authors:  Annette Theodorsson; Elvar Theodorsson
Journal:  Peptides       Date:  2005-11       Impact factor: 3.750

7.  Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.

Authors:  Oliver Gautschi; Clifford G Tepper; Phillip R Purnell; Yoshihiro Izumiya; Christopher P Evans; Tim P Green; Pierre Y Desprez; Primo N Lara; David R Gandara; Philip C Mack; Hsing-Jien Kung
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Intron retention generates a novel Id3 isoform that inhibits vascular lesion formation.

Authors:  Scott T Forrest; Kurt G Barringhaus; Demetra Perlegas; Marie-Louise Hammarskjold; Coleen A McNamara
Journal:  J Biol Chem       Date:  2004-05-24       Impact factor: 5.157

9.  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Authors:  Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

10.  Blood-brain barrier-specific properties of a human adult brain endothelial cell line.

Authors:  B B Weksler; E A Subileau; N Perrière; P Charneau; K Holloway; M Leveque; H Tricoire-Leignel; A Nicotra; S Bourdoulous; P Turowski; D K Male; F Roux; J Greenwood; I A Romero; P O Couraud
Journal:  FASEB J       Date:  2005-09-01       Impact factor: 5.191

View more
  6 in total

Review 1.  Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions.

Authors:  Christian Michael Perez; Quentin Felty
Journal:  Microvasc Res       Date:  2022-02-07       Impact factor: 3.514

2.  Brain infiltration of breast cancer stem cells is facilitated by paracrine signaling by inhibitor of differentiation 3 to nuclear respiratory factor 1.

Authors:  Jayanta K Das; Alok Deoraj; Deodutta Roy; Quentin Felty
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-09       Impact factor: 4.322

3.  Polychlorinated Biphenyls and Pulmonary Hypertension.

Authors:  Hamza Assaggaf; Changwon Yoo; Roberto G Lucchini; Steven M Black; Munerah Hamed; Faisal Minshawi; Quentin Felty
Journal:  Int J Environ Res Public Health       Date:  2022-04-13       Impact factor: 4.614

Review 4.  Contribution of Inhibitor of DNA Binding/Differentiation-3 and Endocrine Disrupting Chemicals to Pathophysiological Aspects of Chronic Disease.

Authors:  Vincent Avecilla; Mayur Doke; Quentin Felty
Journal:  Biomed Res Int       Date:  2017-07-13       Impact factor: 3.411

Review 5.  Inhibitor of Differentiation-3 and Estrogenic Endocrine Disruptors: Implications for Susceptibility to Obesity and Metabolic Disorders.

Authors:  Mayur Doke; Vincent Avecilla; Quentin Felty
Journal:  Biomed Res Int       Date:  2018-01-08       Impact factor: 3.411

Review 6.  Contribution of Inhibitor of Differentiation and Estrogenic Endocrine Disruptors to Neurocognitive Disorders.

Authors:  Andrea Avecilla; Mayur Doke; Jeremy Jovellanos; Vincent Avecilla
Journal:  Med Sci (Basel)       Date:  2018-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.